HARVARD BIOSCIENCE INC (HBIO)
$7.93+$0.03 (+0.38%) Today
Latest HBIO Insider Trades
Stephen J. Denelsky - DirectorOpen-market purchase$49K
Stephen J. Denelsky - DirectorStephen J. Denelsky - DirectorHarvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
https://www.harvardbioscience.comSEC filings for HBIO on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 5 | 82,780 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
20 Form 4 filings on record, the earliest from Dec 31, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Katherine A. Eade - Director | Grant or award | Common Stock | 16,556 | $0.00 | - | |
| William Snider - Director | Grant or award | Common Stock | 16,556 | $0.00 | - | |
| Stephen J. Denelsky - Director | Grant or award | Common Stock | 16,556 | $0.00 | - | |
| Robert E. Gagnon - Director | Grant or award | Common Stock | 16,556 | $0.00 | - | |
| Seth Benjamin Benson - Director | Grant or award | Common Stock | 16,556 | $0.00 | - | |
| Mark T. Frost - Officer | Grant or award | Common Stock | 30,000 | $0.00 | - | |
| John D. Duke - Officer | Grant or award | Common Stock | 75,000 | $0.00 | - | |
| Stephen J. Denelsky - Director | Open-market purchase | Common Stock | 10,000 | $4.87 | $49K | |
| William Snider - Director | Open-market purchase | Common Stock | 12,525 | $4.99 | $62K | |
| William Snider - Director | Open-market purchase | Common Stock | 8,475 | $4.85 | $41K | |
| John D. Duke - Officer | Open-market purchase | Common Stock | 5,000 | $5.01 | $25K | |
| William Snider - Director | Grant or award | Common Stock | 110,000 | $0.00 | - | |
| Stephen J. Denelsky - Director | Grant or award | Common Stock | 110,000 | $0.00 | - | |
 James W. Green - Director | Derivative | Common Stock | 49,048 | $0.00 | - | |
| James W. Green - Director | Tax withholding / forfeiture | Common Stock | 33,200 | $5.29 | $18K | |
| James W. Green - Director | Derivative | Common Stock | 119,332 | $0.00 | - | |
| James W. Green - Director | Tax withholding / forfeiture | Common Stock | 11,540 | $5.29 | $6K | |
| James W. Green - Director | Derivative | Common Stock | 66,036 | $0.00 | - | |
| James W. Green - Director | Derivative | Common Stock | 113,366 | $0.00 | - | |
| John D. Duke - Officer | Grant or award | Common Stock | 500,000 | $0.00 | - | |
| John D. Duke - Officer | Grant or award | Common Stock | 500,000 | $0.00 | - | |
| Seth Benjamin Benson - Director | Grant or award | Common Stock | 110,000 | $0.00 | - | |
| Katherine A. Eade - Director | Grant or award | Common Stock | 110,000 | $0.00 | - | |
| Robert E. Gagnon - Director | Grant or award | Common Stock | 110,000 | $0.00 | - | |
| Mark T. Frost - Officer | Grant or award | Common Stock | 100,000 | $0.00 | - | |
| James W. Green - Officer | Tax withholding / forfeiture | Common Stock | 56,915 | $19.80 | $113K | |
| James W. Green - Officer | Tax withholding / forfeiture | Common Stock | 25,310 | $19.80 | $50K | |
 Jennifer Cote - Officer | Tax withholding / forfeiture | Common Stock | 4,731 | $19.80 | $9K | |
| Jennifer Cote - Officer | Tax withholding / forfeiture | Common Stock | 3,797 | $19.80 | $8K |
HARVARD BIOSCIENCE INC (HBIO) had 5 insider filings in the last 90 days, with the most recent on 2026-06-12. The full record for HBIO runs to 20 Form 4 filings, the earliest from 2024-12-31. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of HBIO were filed in the last 90 days. 4 purchases are on record for this company.
No insider sales of HBIO were filed in the last 90 days.
This page tracks HBIO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add HBIO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
